Clinical evidence supporting the use of an activated clinoptilolite suspension as an agent to increase urinary excretion of toxic heavy metal
2 min read
Abstract: Effective treatment of chronic illness resulting from the long-term buildup of heavy metals in the body, such as chelation therapy, presents numerous clinical challenges, including undesirable side effects and unpredictable efficacy. Use of a naturally occurring zeolite, clinoptilolite, to remove these toxic substances may offer an efficacious and safe alternative to the traditional approaches.
This study was designed to evaluate the ability of activated clinoptilolite suspended in water (ACS) to remove heavy metals from the body through urinary excretion without the undesirable removal of physiologically important electrolytes. The protocol utilized two treatment groups, each consisting of eleven healthy men aged 36 to 70 years. Volunteers were given a commercially available version of the study substance for seven days (Group 1) and 30 days (Group 2) and urine samples were collected at specified time points in the study.
Changes in urinary concentration of the heavy metals were measured by inductively coupled plasma mass spectrometry and compared to the baseline. Also, serum samples were obtained from five individuals in each group and serum electrolytes were measured prior to and after taking the product. Participants in both groups had increased concentrations of heavy metals in the urine with the peak excretion at around day 4.
No clinically significant alterations in serum electrolyte levels were seen at either seven or 30 days on ACS. In conclusion, this study demonstrates that the daily use of an activated clinoptilolite suspension represents a potentially safe and effective way to remove toxic heavy metals from the body through increased urinary excretion without removing clinically detrimental amounts of vital electrolytes.
